Pharm/DUR acquired by ACS

Acquirers in this category assess four things above all: the durability of payer contracts and how much of the revenue base renews without a competitive re-tender; the defensibility of the audit methodology itself, since a process that pharmacies accept and regulators trust is difficult to replicate quickly; proprietary technology that turns paid-claims data into recoverable findings, as AUDITrack did for Pharm/DUR; and independence from the pharmacy benefit managers being audited, which is what allows the firm to act for the programme sponsor without conflict. A specialist with all four is materially harder to build than to buy, and that build-versus-buy calculation is where the valuation premium in a sell-side M&A process comes from.

Businesses of this type sit between a services multiple and a software multiple, and where they land depends on how the revenue is characterised. Recurring or contracted audit revenue with visible renewal history is valued closer to a software basis; project and contingency-fee recovery work is valued closer to a services basis on maintainable EBITDA. Contract length, client concentration, and gross margin move the number more than headline revenue does. The valuation narrative a founder can evidence — not the one they assert — is what a sophisticated acquirer will underwrite, and building that evidence is work that starts well before a UK mid-market M&A process goes to market.

Large groups already hold the payer relationships. What they usually lack is the specialist capability to sell into them, and building an in-store audit operation from nothing requires field auditors, pharmacy trust, and a methodology that survives challenge — none of which can be hired quickly. Acquisition converts a multi-year build into a completed transaction and lets the acquirer cross-sell immediately into contracts it already owns. ACS had signalled exactly this intent five years before acquiring Pharm/DUR, through its purchase of Heritage Information Systems. For founders, recognising that a buyer's stated strategy already points at your category is one of the strongest indicators of genuine strategic fit rather than opportunistic interest.

In capability-led acquisitions the acquirer is buying the people and the client relationships, so retention is usually in its own commercial interest — a payment integrity operation without its auditors is not worth what was paid for it. ACS confirmed at announcement that Pharm/DUR's employees would be unaffected. That said, intent expressed publicly and protection written into deal terms are different things. Team continuity, client servicing commitments, and retention arrangements are negotiable, and they are far easier to secure while competitive tension exists than after exclusivity has been granted. Founders who care about this outcome should raise it early rather than treat it as a completion-stage detail.

Timing is set by three things at once. Personally: whether the founder still wants to lead the next phase, and what they intend to do afterwards. Operationally: whether the business functions when the founder is not in the room, which is the single largest value determinant in owner-managed services firms. Commercially: whether acquirers in the category are actively buying, since a narrow buyer universe with no live appetite cannot be persuaded into competitive tension. Founders who wait until they are tired of the business almost always sell into a weaker position than founders who prepare while momentum is still theirs.

A failed exclusivity is one of the more common ways a process goes wrong, and it is recoverable — but only if the groundwork was laid before exclusivity was granted. What determines the outcome is whether other credible bidders were kept informed rather than dismissed, whether the valuation narrative rested on evidence rather than on the departing buyer's enthusiasm, and whether the founder has the resilience to restart rather than accept reduced terms to end the uncertainty. In the Pharm/DUR transaction the first purchaser to enter exclusivity did not complete; the process was restarted and the eventual acquirer paid a significantly higher price. Assume before you begin that the first buyer may not be the last.

Consolidation runs upwards as well as downwards. A listed acquirer can itself become a target, and when that happens the commitments made to a recently acquired business are inherited by a party that never negotiated them. Xerox acquired ACS in February 2010, seven months after Pharm/DUR completed, and the capability passed into the Xerox healthcare division. Where any consideration is deferred, earnout-linked, or paid in acquirer shares, this matters commercially as well as culturally — the terms should anticipate a change of control rather than assume the counterparty stays the same. Assessing an acquirer's own strategic trajectory is part of buyer due diligence, not an optional extra.

Three tests matter more than firm size. First, whether the advisor can map the buyer universe in the relevant jurisdiction rather than relying on a domestic contact list — a US payer market and a UK mid-market M&A landscape have different acquirers, different valuation conventions, and different regulatory sensitivities. Second, whether they have completed transactions across borders and can coordinate legal and tax advice in both. Third, whether they will tell you when the timing or the terms are wrong, which is a question of incentive structure rather than character. CapEQ is a Certified B Corporation, independently assessed on putting client outcomes ahead of deal income, and Mark Sapsford has completed transactions across the UK, Ireland, the USA, the Netherlands, Australia, Spain, and Poland.